BCDA - BioCardia, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

BioCardia, Inc.

125 Shoreway Road
Suite B
San Carlos, CA 94070
United States
650-226-0120
http://www.biocardia.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees27

Key Executives

NameTitlePayExercisedYear Born
Dr. Peter A. AltmanCEO, Pres & Director360kN/A1967
Mr. David McClungChief Financial Officer300kN/A1963
Mr. Phil PestaVP of Operations235kN/A1966
Dr. Eric Henricus J. DuckersChief Medical Officer350kN/A1968
Dr. Ian McNiece Ph.D.Chief Scientific OfficerN/AN/A1954
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.

Corporate Governance

BioCardia, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.